Amphastar Antitrust Claims Nixed In Lovenox Suit

Law360, New York (February 19, 2009, 12:00 AM EST) -- In a setback for Amphastar Pharmaceuticals Inc., a federal judge has dismissed its cross-claims that two Sanofi-Aventis subsidiaries engaged in anti-competitive conduct and unfair competition by obtaining and enforcing through fraud patents related to Aventis’ anti-clotting drug Lovenox.

Judge Mariana R. Pfaelzer of the U.S. District Court for the Central District of California on Tuesday granted Aventis Pharma SA and Aventis Pharmaceuticals Inc.’s dismissal bid after finding the allegations that were able to survive Noerr-Pennington immunity failed to allege the necessary element of antitrust injury. They...
To view the full article, register now.